Effects of tethered ligands and of metal oxidation state on the interactions of cobalt complexes with the 26S proteasome.

[1]  F. Guissard,et al.  Biochemical Pharmacology , 1960, Nature.

[2]  A. Klegeris,et al.  The synthesis and characterization of a series of cobalt(II) β-ketoaminato complexes and their cytotoxic activity towards human tumor cell lines. , 2011, Journal of inorganic biochemistry.

[3]  C. Parish,et al.  Cellular Up-regulation of Nedd4 Family Interacting Protein 1 (Ndfip1) using Low Levels of Bioactive Cobalt Complexes* , 2010, The Journal of Biological Chemistry.

[4]  J. Rueff,et al.  Synthesis, characterization and cytotoxic activity of gallium(III) complexes anchored by tridentate pyrazole-based ligands. , 2010, Journal of inorganic biochemistry.

[5]  Q. Dou,et al.  Metals in anticancer therapy: copper(II) complexes as inhibitors of the 20S proteasome. , 2009, European journal of medicinal chemistry.

[6]  C. Pinheiro,et al.  Synthesis, characterization and biological activities of mononuclear Co(III) complexes as potential bioreductively activated prodrugs. , 2009, Journal of inorganic biochemistry.

[7]  Di Chen,et al.  Comparative activities of nickel(II) and zinc(II) complexes of asymmetric [NN'O] ligands as 26S proteasome inhibitors. , 2009, Inorganic chemistry.

[8]  K. Stangl,et al.  Proteasome inhibitors: Poisons and remedies , 2008, Medicinal research reviews.

[9]  H. Hratchian,et al.  Archetypical modeling and amphiphilic behavior of cobalt(II)-containing soft-materials with asymmetric tridentate ligands. , 2007, Inorganic chemistry.

[10]  Di Chen,et al.  Inhibition of the proteasome activity by gallium(III) complexes contributes to their anti prostate tumor effects. , 2007, Cancer research.

[11]  M. Hall,et al.  Bioreductive activation and drug chaperoning in cobalt pharmaceuticals. , 2007, Dalton transactions.

[12]  Di Chen,et al.  The Therapeutic Potential of Gallium-Based Complexes in Anti-Tumor Drug Design , 2007 .

[13]  M. Groll,et al.  20S proteasome and its inhibitors: crystallographic knowledge for drug development. , 2007, Chemical reviews.

[14]  Q Ping Dou,et al.  Disulfiram, a clinically used anti-alcoholism drug and copper-binding agent, induces apoptotic cell death in breast cancer cultures and xenografts via inhibition of the proteasome activity. , 2006, Cancer research.

[15]  Jianguo Liu,et al.  Synthesis, structure, and anticancer activity of gallium(III) complexes with asymmetric tridentate ligands: growth inhibition and apoptosis induction of cisplatin-resistant neuroblastoma cells. , 2006, Inorganic chemistry.

[16]  H. Schlegel,et al.  Structural, spectroscopic, and electrochemical behavior of trans-phenolato cobalt(III) complexes of asymmetric NN'O ligands as archetypes for metallomesogens. , 2006, Dalton transactions.

[17]  A. Bortoluzzi,et al.  Electronic effects of electron-donating and -withdrawing groups in model complexes for iron-tyrosine-containing metalloenzymes. , 2006, Inorganic chemistry.

[18]  Lan Huang,et al.  Global approaches to understanding ubiquitination , 2005, Genome Biology.

[19]  H. Schlegel,et al.  Influence of ligand rigidity and ring substitution on the structural and electronic behavior of trivalent iron and gallium complexes with asymmetric tridentate ligands. , 2005, Inorganic chemistry.

[20]  Di Chen,et al.  Clioquinol and pyrrolidine dithiocarbamate complex with copper to form proteasome inhibitors and apoptosis inducers in human breast cancer cells , 2005, Breast Cancer Research.

[21]  A. Mangrich,et al.  Synthesis, characterization and structure of a new zinc(II) complex containing the hexadentate N,N′,N,N′-bis[(2-hydroxy-3,5-di-tert-butylbenzyl)(2-pyridylmethyl)]-ethylenediamine ligand: Generation of phenoxyl radical species , 2005 .

[22]  Jakob R. Winther,et al.  Monitoring disulfide bond formation in the eukaryotic cytosol , 2004, The Journal of cell biology.

[23]  W. Guida,et al.  Organic copper complexes as a new class of proteasome inhibitors and apoptosis inducers in human cancer cells. , 2004, Biochemical pharmacology.

[24]  C. Orvig,et al.  Cationic iron(III) complex with a hexadentate N2,N'2',O2-aminopyridylphenolate ligand , 1999 .

[25]  Q. Dou,et al.  Novel dipeptidyl proteasome inhibitors overcome Bcl-2 protective function and selectively accumulate the cyclin-dependent kinase inhibitor p27 and induce apoptosis in transformed, but not normal, human fibroblasts , 1998, Cell Death and Differentiation.

[26]  A. Neves,et al.  A comparison between the structures of [MnIII(bbpen)][PF6] and [MnIII(bbppn)][PF6] (H2bbpen=N,N′-bis(2-hydroxybenzyl)-N,N′-(2-pyridylmethyl)ethylenediamine, H2bbppn=N,N′-bis(2-hydroxybenzyl)-N,N′-(2-pyridylmethyl)-1,3-propanediamine) , 1997 .

[27]  Shuang Liu,et al.  Gallium and Indium Complexes of Hexadentate Ligands Containing Pendant Pyridyl and Phenolate Groups , 1995 .

[28]  A. Neves,et al.  Synthesis, crystal structure, electrochemical, and spectroelectrochemical properties of the new manganese(III) complex [MnIII(BBPEN)][PF6] [H2BBPEN = N,N'-bis(2-hydroxybenzyl)-N,N'-bis(2-methylpyridyl)ethylenediamine] , 1992 .

[29]  G. Sheldrick.  A short history of SHELX. , 2008, Acta crystallographica. Section A, Foundations of crystallography.

[30]  A. Goldberg,et al.  Proteasome inhibitors: from research tools to drug candidates. , 2001, Chemistry & biology.

[31]  M. Hochstrasser.  Ubiquitin, proteasomes, and the regulation of intracellular protein degradation. , 1995, Current opinion in cell biology.

[32]  J. Kendall.  Inorganic Chemistry , 1944, Nature.